Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.

Helius Medical Technologies, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEWTOWN, PA., JULY 21, 2025 (GLOBE NEWSWIRE) -- HELIUS MEDICAL TECHNOLOGIES, INC. (NASDAQ: HSDT), A NEUROTECH COMPANY FOCUSED ON DELIVERING A NOVEL THERAPEUTIC NEUROMODULATION APPROACH FOR BALANCE AND GAIT DEFICITS, TODAY ANNOUNCED POSITIVE OUTCOME FROM THE PONS (PORTABLE NEUROMODULATION STIMULATOR) STROKE REGISTRATIONAL PROGRAM (SRP) SUPPORTING A PLANNED FDA SUBMISSION SEEKING AN INDICATION FOR GAIT AND BALANCE DEFICIT IN PATIENTS WITH CHRONIC SYMPTOMS OF STROKE UNDER THE CURRENT BREAKTHROUGH DEVICE DESIGNATION.

HELIUS ANNOUNCES POSITIVE OUTCOME OF THE PORTABLE NEUROMODULATION STIMULATOR PONS STROKE REGISTRATIONAL PROGRAM AND UPCOMING SUBMISSION TO FDA UNDER BREAKTHROUGH DESIGNATION

NEWTOWN, PA., JULY 09, 2025 (GLOBE NEWSWIRE) -- HELIUS MEDICAL TECHNOLOGIES, INC. (NASDAQ: HSDT) (HELIUS OR THE COMPANY), A NEUROTECH COMPANY FOCUSED ON DELIVERING A NOVEL THERAPEUTIC NEUROMODULATION APPROACH FOR BALANCE AND GAIT DEFICITS,TODAY ANNOUNCED THAT ON JULY 7, 2025, HELIUS RECEIVED FORMAL NOTICE FROM THE NASDAQ HEARINGS PANEL OF THE NASDAQ STOCK MARKET LLC (THE PANEL) INDICATING THAT HELIUS HAS EVIDENCED COMPLIANCE WITH THE EQUITY REQUIREMENT IN LISTING RULE 5550(B)(1) (THE EQUITY RULE) FOR CONTINUED LISTING ON THE NASDAQ CAPITAL MARKET.

HELIUS MEDICAL TECHNOLOGIES, INC. COMPLIANT WITH NASDAQ'S CONTINUED LISTING REQUIREMENTS

NEWTOWN, PA., JUNE 27, 2025 (GLOBE NEWSWIRE) -- HELIUS MEDICAL TECHNOLOGIES, INC. (NASDAQ:HSDT) (HELIUS OR THE COMPANY), A NEUROTECH COMPANY FOCUSED ON DELIVERING A NOVEL THERAPEUTIC NEUROMODULATION APPROACH FOR BALANCE AND GAIT DEFICITS, ANNOUNCED TODAY A 1-FOR-50 REVERSE SPLIT OF ITS CLASS A COMMON STOCK, PAR VALUE $0.001 (COMMON STOCK), EFFECTIVE AT 5:00 PM EASTERN TIME ON JUNE 30, 2025. BEGINNING ON JULY 1, 2025, THE COMPANY'S COMMON STOCK WILL TRADE ON THE NASDAQ CAPITAL MARKET ON A SPLIT ADJUSTED BASIS.

HELIUS MEDICAL TECHNOLOGIES ANNOUNCES REVERSE STOCK SPLIT

- CIGNAHEALTH BECOMES FIFTH MAJOR PAYER TO AUTHORIZE CLAIM FOR PONS DEVICE AT OUT-OF-NETWORK ADJUSTED NEGOTIATED LIST PRICE OF $19,161- -THIS FOLLOWS ANOTHER RECENT AUTHORIZATION BY ANTHEM MULTIPLAN FOR PONS DEVICE AT OUT-OF-NETWORK NEGOTIATED PRICE OF $19,160- NEWTOWN, PA., JUNE 16, 2025 (GLOBE NEWSWIRE) -- HELIUS MEDICAL TECHNOLOGIES, INC. (NASDAQ: HSDT) (HELIUS OR THE COMPANY), A NEUROTECH COMPANY FOCUSED ON DELIVERING A NOVEL THERAPEUTIC NEUROMODULATION APPROACH FOR BALANCE AND GAIT DEFICITS,TODAY ANNOUNCED AN ADDITIONAL AUTHORIZED CLAIM FOR PAYMENT FOR THE PONS DEVICE FROM CIGNAHEALTH.

HELIUS MEDICAL TECHNOLOGIES, INC. ANNOUNCES CLAIM AUTHORIZATION BY CIGNAHEALTH, FOR ITS PORTABLE NEUROMODULATION STIMULATOR (PONS) DEVICE

-PONS THERAPEUTIC EXPERIENCE PROGRAM (PONSTEP) STUDY DEMONSTRATES DURABLE LONG-TERM BENEFICIAL EFFECTS OF PONS THERAPY ON GAIT DEFICIT IMPROVEMENT IN PEOPLE WITH MULTIPLE SCLEROSIS-

POSITIVE PONSTEP STUDY RESULTS PRESENTED AT CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS ANNUAL MEETING

-AETNA AUTHORIZES CLAIM FOR PONS DEVICE AT OUT-OF-NETWORK NEGOTIATED PRICE OF $18,350, BECOMING THE THIRD PAYER TO JOIN ANTHEM AND UNITED IN PROVIDING PONS REIMBURSEMENT-

HELIUS MEDICAL TECHNOLOGIES, INC. ANNOUNCES AUTHORIZED CLAIM FOR PAYMENT BY MAJOR HEALTHCARE PAYER FOR ITS PORTABLE NEUROMODULATION STIMULATOR (PONS) DEVICE

NEWTOWN, PA., JUNE 04, 2025 (GLOBE NEWSWIRE) -- HELIUS MEDICAL TECHNOLOGIES, INC. (NASDAQ: HSDT) (HELIUS OR THE COMPANY), A NEUROTECH COMPANY FOCUSED ON DELIVERING A NOVEL THERAPEUTIC NEUROMODULATION APPROACH FOR BALANCE AND GAIT DEFICITS, TODAY ANNOUNCED THE PRICING OF ITS PUBLIC OFFERING OF AN AGGREGATE OF 2,768,600 SHARES OF ITS CLASS A COMMON STOCK (OR COMMON STOCK EQUIVALENTS), AND WARRANTS TO PURCHASE UP TO 2,768,600 SHARES OF COMMON STOCK, AT A COMBINED PUBLIC OFFERING PRICE OF $3.27 PER SHARE AND ACCOMPANYING WARRANTS.

HELIUS MEDICAL TECHNOLOGIES ANNOUNCES PRICING OF $9.1 MILLION PUBLIC OFFERING

COMPANY PREVIOUSLY GRANTED EXTENSION UNTIL JUNE 30, 2025 TO REGAIN COMPLIANCE WITH NASDAQ'S EQUITY RULE REQUIREMENT COMPANY PREVIOUSLY GRANTED EXTENSION UNTIL JUNE 30, 2025 TO REGAIN COMPLIANCE WITH NASDAQ'S EQUITY RULE REQUIREMENT

HELIUS MEDICAL TECHNOLOGIES, INC. COMPLIANT WITH NASDAQ BID PRICE RULE LISTING CRITERIA

SHEPHERD CENTER'S DR. DEBORAH BACKUS TO SHOWCASE FINAL RESULTS OF PONSTEP STUDY, PROVIDING NEW INSIGHT INTO MAXIMIZING IMPACT OF NEUROMODULATION TO IMPROVE GAIT IN PEOPLE WITH MS SHEPHERD CENTER'S DR. DEBORAH BACKUS TO SHOWCASE FINAL RESULTS OF PONSTEP STUDY, PROVIDING NEW INSIGHT INTO MAXIMIZING IMPACT OF NEUROMODULATION TO IMPROVE GAIT IN PEOPLE WITH MS

HELIUS TO SPOTLIGHT STUDY CONFIRMING IMPROVED LONG-TERM OUTCOMES FROM ADHERENCE TO PONS THERAPY AT CMSC ANNUAL MEETING

UNITED HEALTHCARE APPROVES CLAIM FOR PONS DEVICE AT OUT-OF-NETWORK ADJUSTED LIST PRICE, BECOMING THE SECOND PAYER TO JOIN ANTHEM IN PROVIDING PONS REIMBURSEMENT UNITED HEALTHCARE APPROVES CLAIM FOR PONS DEVICE AT OUT-OF-NETWORK ADJUSTED LIST PRICE, BECOMING THE SECOND PAYER TO JOIN ANTHEM IN PROVIDING PONS REIMBURSEMENT

Helius Medical Technologies, Inc.

HSDT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Helius Medical Technologies, Inc.

HSDT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

HSDT